These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19236436)

  • 1. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation.
    Hammond EB; Taber DJ; Weimert NA; Egidi MF; Bratton CF; Lin A; McGillicuddy JW; Chavin KD; Baliga PK
    Clin Transplant; 2010; 24(1):40-7. PubMed ID: 19236436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database.
    Jindal RM; Das NP; Neff RT; Hurst FP; Falta EM; Elster EA; Abbott KC
    Am J Nephrol; 2009; 29(6):501-8. PubMed ID: 19060477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
    Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
    Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
    Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
    Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients.
    Lo YC; Ho HC; Wu MJ; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Yang CK; Shu KH
    Ren Fail; 2012; 34(7):856-61. PubMed ID: 22583338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
    Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
    Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
    Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
    Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.
    Zhang Y; Jin W; Cai X
    Ann Med; 2017 Aug; 49(5):365-376. PubMed ID: 27813419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Daclizumab in a high-risk renal transplant population.
    Meier-Kriesche HU; Kaza H; Palekar SS; Friedman GS; Mulgaonkar SP; Ojo AO; Kaplan B
    Clin Transplant; 2000 Oct; 14(5):509-13. PubMed ID: 11048998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
    Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
    Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
    Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
    Deeks ED; Keating GM
    Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
    Noël C; Abramowicz D; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Hazzan M
    J Am Soc Nephrol; 2009 Jun; 20(6):1385-92. PubMed ID: 19470677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.